Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells

Zheqi Li, Kevin M. Levine, Amir Bahreini, Peilu Wang, David Chu, Ben Ho Park, Steffi Oesterreich, Adrian V. Lee

Research output: Contribution to journalArticle

Abstract

Increased evidence suggests that somatic mutations in the ligand-binding domain of estrogen receptor [ER (ERa/ESR1)] are critical mediators of endocrine-resistant breast cancer progression. Insu-linlike growth factor-1 (IGF1) is an essential regulator of breast development and tumorigenesis and also has a role in endocrine resistance. A recent study showed enhanced crosstalk between IGF1 and ERa in ESR1 mutant cells, but detailed mechanisms are incompletely understood. Using genome-edited MCF-7 and T47D cell lines harboring Y537S and D538G ESR1 mutations, we characterized altered IGF1 signaling. RNA sequencing revealed upregulation of multiple genes in the IGF1 pathway, including insulin receptor substrate-1 (IRS1), consistent in both Y537S and D538G ESR1 mutant cell line models. Higher IRS1 expression was confirmed by quantitative reverse transcription polymerase chain reaction and immunoblotting. ESR1 mutant cells also showed increased levels of IGF-regulated genes, reflected by activation of an IGF signature. IGF1 showed increased sensitivity and potency in growth stimulation of ESR1 mutant cells. Analysis of downstream signaling revealed the phosphoinositide 3-kinase (PI3K)–Akt axis as a major pathway mediating the enhanced IGF1 response in ESR1 mutant cells. Decreasing IRS1 expression by small interfering RNA diminished the increased sensitivity to IGF1. Combination treatment with inhibitors against IGF1 receptor (IGF1R; OSI-906) and ER (fulvestrant) showed synergistic growth inhibition in ESR1 mutant cells, particularly at lower effective concentrations. Our study supports a critical role of enhanced IGF1 signaling in ESR1 mutant cell lines, pointing toward a potential for cotargeting IGF1R and ERa in endocrine-resistant breast tumors with mutant ESR1.

Original languageEnglish (US)
Pages (from-to)285-296
Number of pages12
JournalEndocrinology
Volume159
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Insulin Receptor Substrate Proteins
Intercellular Signaling Peptides and Proteins
Up-Regulation
Breast Neoplasms
Cell Line
RNA Sequence Analysis
Mutation
1-Phosphatidylinositol 4-Kinase
Growth Factor Receptors
MCF-7 Cells
Growth
Immunoblotting
Estrogen Receptors
Small Interfering RNA
Transcriptional Activation
Reverse Transcription
Carcinogenesis
Breast
Genome
Ligands

ASJC Scopus subject areas

  • Endocrinology

Cite this

Li, Z., Levine, K. M., Bahreini, A., Wang, P., Chu, D., Park, B. H., ... Lee, A. V. (2018). Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells. Endocrinology, 159(1), 285-296. https://doi.org/10.1210/en.2017-00693

Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells. / Li, Zheqi; Levine, Kevin M.; Bahreini, Amir; Wang, Peilu; Chu, David; Park, Ben Ho; Oesterreich, Steffi; Lee, Adrian V.

In: Endocrinology, Vol. 159, No. 1, 01.01.2018, p. 285-296.

Research output: Contribution to journalArticle

Li, Z, Levine, KM, Bahreini, A, Wang, P, Chu, D, Park, BH, Oesterreich, S & Lee, AV 2018, 'Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells', Endocrinology, vol. 159, no. 1, pp. 285-296. https://doi.org/10.1210/en.2017-00693
Li, Zheqi ; Levine, Kevin M. ; Bahreini, Amir ; Wang, Peilu ; Chu, David ; Park, Ben Ho ; Oesterreich, Steffi ; Lee, Adrian V. / Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells. In: Endocrinology. 2018 ; Vol. 159, No. 1. pp. 285-296.
@article{ad267c644ee4417e8bd0801b37e400dc,
title = "Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells",
abstract = "Increased evidence suggests that somatic mutations in the ligand-binding domain of estrogen receptor [ER (ERa/ESR1)] are critical mediators of endocrine-resistant breast cancer progression. Insu-linlike growth factor-1 (IGF1) is an essential regulator of breast development and tumorigenesis and also has a role in endocrine resistance. A recent study showed enhanced crosstalk between IGF1 and ERa in ESR1 mutant cells, but detailed mechanisms are incompletely understood. Using genome-edited MCF-7 and T47D cell lines harboring Y537S and D538G ESR1 mutations, we characterized altered IGF1 signaling. RNA sequencing revealed upregulation of multiple genes in the IGF1 pathway, including insulin receptor substrate-1 (IRS1), consistent in both Y537S and D538G ESR1 mutant cell line models. Higher IRS1 expression was confirmed by quantitative reverse transcription polymerase chain reaction and immunoblotting. ESR1 mutant cells also showed increased levels of IGF-regulated genes, reflected by activation of an IGF signature. IGF1 showed increased sensitivity and potency in growth stimulation of ESR1 mutant cells. Analysis of downstream signaling revealed the phosphoinositide 3-kinase (PI3K)–Akt axis as a major pathway mediating the enhanced IGF1 response in ESR1 mutant cells. Decreasing IRS1 expression by small interfering RNA diminished the increased sensitivity to IGF1. Combination treatment with inhibitors against IGF1 receptor (IGF1R; OSI-906) and ER (fulvestrant) showed synergistic growth inhibition in ESR1 mutant cells, particularly at lower effective concentrations. Our study supports a critical role of enhanced IGF1 signaling in ESR1 mutant cell lines, pointing toward a potential for cotargeting IGF1R and ERa in endocrine-resistant breast tumors with mutant ESR1.",
author = "Zheqi Li and Levine, {Kevin M.} and Amir Bahreini and Peilu Wang and David Chu and Park, {Ben Ho} and Steffi Oesterreich and Lee, {Adrian V.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1210/en.2017-00693",
language = "English (US)",
volume = "159",
pages = "285--296",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells

AU - Li, Zheqi

AU - Levine, Kevin M.

AU - Bahreini, Amir

AU - Wang, Peilu

AU - Chu, David

AU - Park, Ben Ho

AU - Oesterreich, Steffi

AU - Lee, Adrian V.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Increased evidence suggests that somatic mutations in the ligand-binding domain of estrogen receptor [ER (ERa/ESR1)] are critical mediators of endocrine-resistant breast cancer progression. Insu-linlike growth factor-1 (IGF1) is an essential regulator of breast development and tumorigenesis and also has a role in endocrine resistance. A recent study showed enhanced crosstalk between IGF1 and ERa in ESR1 mutant cells, but detailed mechanisms are incompletely understood. Using genome-edited MCF-7 and T47D cell lines harboring Y537S and D538G ESR1 mutations, we characterized altered IGF1 signaling. RNA sequencing revealed upregulation of multiple genes in the IGF1 pathway, including insulin receptor substrate-1 (IRS1), consistent in both Y537S and D538G ESR1 mutant cell line models. Higher IRS1 expression was confirmed by quantitative reverse transcription polymerase chain reaction and immunoblotting. ESR1 mutant cells also showed increased levels of IGF-regulated genes, reflected by activation of an IGF signature. IGF1 showed increased sensitivity and potency in growth stimulation of ESR1 mutant cells. Analysis of downstream signaling revealed the phosphoinositide 3-kinase (PI3K)–Akt axis as a major pathway mediating the enhanced IGF1 response in ESR1 mutant cells. Decreasing IRS1 expression by small interfering RNA diminished the increased sensitivity to IGF1. Combination treatment with inhibitors against IGF1 receptor (IGF1R; OSI-906) and ER (fulvestrant) showed synergistic growth inhibition in ESR1 mutant cells, particularly at lower effective concentrations. Our study supports a critical role of enhanced IGF1 signaling in ESR1 mutant cell lines, pointing toward a potential for cotargeting IGF1R and ERa in endocrine-resistant breast tumors with mutant ESR1.

AB - Increased evidence suggests that somatic mutations in the ligand-binding domain of estrogen receptor [ER (ERa/ESR1)] are critical mediators of endocrine-resistant breast cancer progression. Insu-linlike growth factor-1 (IGF1) is an essential regulator of breast development and tumorigenesis and also has a role in endocrine resistance. A recent study showed enhanced crosstalk between IGF1 and ERa in ESR1 mutant cells, but detailed mechanisms are incompletely understood. Using genome-edited MCF-7 and T47D cell lines harboring Y537S and D538G ESR1 mutations, we characterized altered IGF1 signaling. RNA sequencing revealed upregulation of multiple genes in the IGF1 pathway, including insulin receptor substrate-1 (IRS1), consistent in both Y537S and D538G ESR1 mutant cell line models. Higher IRS1 expression was confirmed by quantitative reverse transcription polymerase chain reaction and immunoblotting. ESR1 mutant cells also showed increased levels of IGF-regulated genes, reflected by activation of an IGF signature. IGF1 showed increased sensitivity and potency in growth stimulation of ESR1 mutant cells. Analysis of downstream signaling revealed the phosphoinositide 3-kinase (PI3K)–Akt axis as a major pathway mediating the enhanced IGF1 response in ESR1 mutant cells. Decreasing IRS1 expression by small interfering RNA diminished the increased sensitivity to IGF1. Combination treatment with inhibitors against IGF1 receptor (IGF1R; OSI-906) and ER (fulvestrant) showed synergistic growth inhibition in ESR1 mutant cells, particularly at lower effective concentrations. Our study supports a critical role of enhanced IGF1 signaling in ESR1 mutant cell lines, pointing toward a potential for cotargeting IGF1R and ERa in endocrine-resistant breast tumors with mutant ESR1.

UR - http://www.scopus.com/inward/record.url?scp=85040740863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040740863&partnerID=8YFLogxK

U2 - 10.1210/en.2017-00693

DO - 10.1210/en.2017-00693

M3 - Article

C2 - 29029116

AN - SCOPUS:85040740863

VL - 159

SP - 285

EP - 296

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -